Mesenchymal stem cells (MSCs) are multipotent stem cells with a high capacity for self-renewal. They can develop into specialized cells of the body such as chondrocytes, osteoblasts, and adipocytes, and their easy accessibility, exceptional genomic stability, and capacity for tissue repair with few immunological and ethical issues make them a favorable cell type for experimental and clinical use. Furthermore, MSCs derived from neonatal tissues have shown greater proliferative capacity and lower immunogenicity than adult bone marrow-derived MSCs. Human chorionic villi-derived mesenchymal stem cells (hCV-MSCs; isolated from the fetal portion of the placenta) have been shown to exhibit reduced telomere loss and senescence onset delay in vitro, as well as a more heterogeneous cell population than other placental MSCs.
hCV-MSCs were isolated from the chorionic villi of the placenta (female offspring). The cells are cultured, passaged for purity, cryopreserved, and delivered frozen. Each vial contains 1 x 106 cells in 1 mL volume. Cells are characterized by flow cytometry for CD90, CD105, CD73, CD45, and CD34. hCV-MSCs are negative for mycoplasma, yeast, fungi, and bacteria. HIV-1, HIV-2, and HBV are not detected. Cells are assured to further culture using the protocol provided by JangoCell.
Human Material Precaution
Tissues used for cell isolation were acquired with informed consent and adhere to HIPAA standards for human privacy protection. All human biological material, including human cells, should always be handled as potentially infectious using at least Biosafety Level 2 precautions; we recommend that appropriate safety procedures be followed, using the same biosafety protocol used with known infectious material. Viral testing cannot prove the absence of a latent viral genome.
